Sulfadimethoxine

Summary

Sulfadimethoxine (CHEMBL62193) is an approved small-molecule antiinfective agent (ATC J01ED01); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01ED01
• Indications: 1 condition
• Chemistry: 310.33 Da · C12H14N4O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL62193
Name	Sulfadimethoxine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5323
ChEBI	CHEBI:32161
ATC	J01ED01
Molecular formula	C12H14N4O4S
Molecular weight	310.33
InChIKey	ZZORFUFYDOWNEF-UHFFFAOYSA-N

SMILES: COC1=NC(=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N)OC

IUPAC name: 4-amino-N-(2,6-dimethoxypyrimidin-4-yl)benzenesulfonamide

ChEBI definition: A sulfonamide consisting of pyrimidine having methoxy substituents at the 2- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position.

Pharmacological roles (ChEBI): antiinfective agent, antimicrobial agent, drug allergen.

Other ChEBI roles (chemical / environmental): xenobiotic, environmental contaminant.

Also known as: Madribon, NSC-683544, NSC-757860, Sulfadimethoxine, Sulfadimetoxina, sulfadimethoxine, SID11112268, SID26747078, SID855993, SID56424126, SID144203956, SULFADIMETHOXINE

Parent form; salt/anhydrous children: CHEMBL2107253

Patent coverage: 2,443 distinct patent families (7,408 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 7,387 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Prelamin-A/C, 5-hydroxytryptamine receptor 6, Cytochrome P450 3A4, Cruzipain, Aldehyde dehydrogenase 1A1, Lethal factor.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 8 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	8.74	Potency	1.8	nM	CHEMBL_ACT_3650330
P15917	6.6	Potency	251.2	nM	CHEMBL_ACT_4633604
HTR6	6.21	Ki	622	nM	CHEMBL_ACT_7818466
HTR6	5.87	IC50	1339	nM	CHEMBL_ACT_7818465
ALDH1A1	5.35	Potency	4467	nM	CHEMBL_ACT_4146256
P25779	5.2	Potency	6310	nM	CHEMBL_ACT_3984672

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).